Clinical trials: Opioid Users
Opioid-use Disorder, Hiv
Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up
The Primary Objective of this study is to compare the effectiveness of HIV clinic-based extended-release Naltrexone (XR-NTX) in decreasing substance use and increasing HIV viral suppression in HIV-infected participants with…
- Trial name
- NCT03275350
- Testing
- Naltrexone Injectable Suspension, Treatment as usual
- Where
- 5 sites in United States
- Volunteers
- 114 people
- Sponsor
- Oregon Health and Science University
Clinical Decision Support, Buprenorphine
Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD
Emergency Departments (EDs) frequently care for individuals with Opioid Use Disorder (OUD). Buprenorphine (BUP) is an effective treatment option for patients with OUD that can safely be initiated in the ED.
- Conditions
- Clinical Decision Support, Buprenorphine, Opioid-use Disorder
- Trial name
- EMBED (NCT03658642)
- Testing
- Clinical Decision Support (CDS)
- Where
- 22 sites in United States
- Volunteers
- 5,047 people
- Sponsor
- Yale University
Cocaine Dependence, Opiate Dependence
A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment
The main goal of this study is to evaluate the safety and tolerability of 40 or 80 mg atomoxetine as a treatment for cocaine dependence.
- Trial name
- NCT01802515
- Testing
- Atomoxetine, low dose, Atomoxetine, high dose
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Yale University
Opioid Abuse
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent…
- Trial name
- NCT01030406
- Testing
- 40/0mg taken first, 80/0mg taken first, 40/240mg taken first
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Opioid Use Disorder
A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
Significant public health concerns have arisen from the intravenous misuse of oxymorphone, a potent mu-opioid pain medication. However, little is known about its abuse potential relative to other mu-opioid analgesics.
- Trial name
- NCT03389750
- Testing
- Intravenous Challenge Drug
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.
- Trial name
- NCT01746901
- Testing
- intact ALO-02 60 mg/7.2 mg, crushed ALO-02 60 mg/7.2 mg, crushed oxycodone IR 60 mg
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nondependent Opioid Abuse, Episodic
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to…
- Trial name
- NCT01380093
- Testing
- MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted
The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused when they are crushed and snorted.
- Trial name
- NCT01775189
- Testing
- crushed ALO-02 30 mg/3.6 mg, crushed oxycodone IR 30 mg
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
Heroin Dependence
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
The study is designed to compare the abuse liabilities of intranasal buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine.
- Trial name
- NCT01760473
- Testing
- Intranasal challenge drug
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid-use Disorder
Buprenorphine Treatment Engagement and Overdose Prevention
Office-based buprenorphine could be expanded to treat many of the opioid users who are not in treatment and who are at great risk for opioid overdose, but effective approaches are needed to help individuals with opioid use…
- Trial name
- NCT03677986
- Testing
- Video DOT+
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Johns Hopkins University
Methamphetamine Abuse, HIV
Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
The purpose of this protocol is to learn more about impulsive decision making in people who use methamphetamines. The investigators would like to know if a medication called naltrexone changes how people make decisions.
- Trial name
- NCT01822132
- Testing
- Extended release naltrexone
- Where
- 2 sites in United States
- Volunteers
- 76 people
- Sponsor
- Oregon Health and Science University
Parenting, Parent-Child Relations
Parenting Young Children Study
Opioid use is rising at unprecedented levels and has reached epidemic proportions in some areas of the country, particularly rural areas.
- Conditions
- Parenting, Parent-Child Relations, Opioid Misuse, Opioid Use Disorder
- Trial name
- NCT05180487
- Testing
- Family Check-Up
- Where
- United States
- Volunteers
- 356 people, healthy volunteers welcome
- Sponsor
- University of Oregon
Abuse Potential
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
This will be a randomized, double-blind, double-dummy, placebo- and active-controlled, 6 treatment, 6-period crossover single-dose, Williams square design study in healthy male and/or female adult, non-drug-dependent recreational…
- Trial name
- NCT05319756
- Testing
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Viatris Specialty LLC
Opioid Use Disorder, Alcohol Use Disorder
Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study
The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and…
- Trial name
- CHOICES (NCT01908062)
- Testing
- Extended Release Naltrexone, Treatment As usual
- Where
- 2 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Oregon Health and Science University
Healthy
Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)
The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).
- Trial name
- NCT00955110
- Testing
- Oxymorphone ER, Oxycodone CR, Hydromorphone
- Where
- Canada
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Opioid-related Disorders
Abuse Liability of Suboxone Versus Subutex
The study is designed to compare the abuse liabilities of intravenous buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine.
- Trial name
- NCT00710385
- Testing
- Heroin, Naloxone, Low Bup Dose
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute